946-61-2

Usage

Uses

Used in Pharmaceutical Research:
Methiothepin is utilized as a research compound for studying the effects of serotonin on the central nervous system. Its antagonistic properties allow scientists to explore the role of serotonin in a range of physiological and behavioral processes.
Used in Psychiatry and Neurology:
In the field of psychiatry and neurology, methiothepin is used as a potential therapeutic agent for conditions such as schizophrenia, anxiety, and depression. Its mechanism of action, which involves blocking serotonin receptor activity, is believed to contribute to the modulation of symptoms associated with these disorders.
Used in Pain Management Research:
Methiothepin is also studied for its potential role in modulating pain perception. As a serotonin receptor antagonist, it may offer insights into the management of pain and the development of novel analgesic therapies.
Used in Appetite Regulation Studies:
Furthermore, methiothepin has been investigated for its impact on appetite regulation. Understanding its effects on serotonin signaling pathways could lead to advancements in the treatment of eating disorders and obesity.
Overall, 2-(4-methoxyphenylamino)-2-thioxoacetic acid, or methiothepin, is a significant compound in the realm of pharmaceutical and neurological research, with potential applications in the development of treatments for a variety of psychiatric and neurological disorders.

Upstream product

• 69066-35-9 (4-Methoxy-phenylamino)-thioxo-acetic acid ethyl ester 
• 24439-54-1 methyl 2-((4-methoxyphenyl)amino)-2-oxoacetate 
• 104-94-9 4-methoxy-aniline 
• 71369-81-8 2-(4-methoxyphenylamino)-2-thioxoacetamide 

Downstream Products

• 946-13-4 6-methoxybenzo[d]thiazol-2-carboxylic acid 

Relevant academic research and scientific papers

Inhibitors of fumarylacetoacetate hydrolase domain containing protein 1 (Fahd1)

FAH domain containing protein 1 (FAHD1) acts as oxaloacetate decarboxylase in mitochondria, contributing to the regulation of the tricarboxylic acid cycle. Guided by a high-resolution X-ray structure of FAHD1 liganded by oxalate, the enzymatic mechanism of substrate processing is analyzed in detail. Taking the chemical features of the FAHD1 substrate oxaloacetate into account, the potential inhibitor structures are deduced. The synthesis of drug-like scaffolds afforded first-generation FAHD1-inhibitors with activities in the low micromolar IC50 range. The investigations disclosed structures competing with the substrate for binding to the metal cofactor, as well as scaffolds, which may have a novel binding mode to FAHD1.

A new synthesis of 2-cyano-6-hydroxybenzothiazole, the key intermediate of d-luciferin, starting from 1,4-benzoquinone

2-Cyano-6-hydroxybenzothiazole is the key intermediate for the synthesis of d-luciferin, the natural substrate of firefly luciferases. A new synthesis of 2-cyano-6-hydroxybenzothiazole has been realized starting from the reaction of 1,4-benzoquinone with l-cysteine ethyl ester, followed by oxidation-cyclization of the intermediate ethyl (R)-2-amino-3-(2,5-dihydroxyphenylsulfanyl)propan-oate hydrochloride to 2-carbethoxy-6-hydroxybenzothiazole. A suitable protection of this intermediate and a conversion to the corresponding nitrile gave, after deprotection, 2-cyano-6-hydroxybenzothiazole (32% yield from 1,4-benzoquinone). This nitrile reacts with d-cysteine to afford d-luciferin at room temperature in nearly quantitative yield (90-95%).

New approach to the synthesis of 2-carbamoylbenzothiazoles

The reactions of substituted anilines with chloroacetamide and sulfur in the presence of triethylamine afforded monothiooxamides. When treated with K3Fe(CN)6, the latter underwent cyclization to form 2-carbamoyIbenzothiazoles. The reactions were accompanied by the formation of the corresponding thiooxanilic acids, which also underwent cyclization to form benzothiazole-2-carboxylic acids.